According to the SEC’s order, BD determined in 2016 that software changes made to the Alaris pump required regulatory clearance from the Food and Drug Administration (FDA). However, BD did not ...

BD decided to continue to selling the Alaris pumps with the improvement without the clearance for it. The SEC said that by January 2019, the company found more than 25 flaws with the software that ...

BD had a run-in with the SEC involving its BD Alaris Infusion System line and how it was presented to investors through its filings from 2020. Without admitting or denying fault, the company has ...